CSL Ltd. shares advanced 5% to an over six-month peak of A$165.88 on Wednesday, outpacing a 0.3% decline in the ASX 200 index.
The rally followed the company’s full-year 2026 results and updated fiscal 2027 guidance. CSL projected approximately 5% growth in underlying net profit after tax for FY27 at constant currency, exceeding the roughly 2% consensus estimate. The company also announced an on-market share buyback valued at A$1.1 billion.
FY26 total revenue totaled US$15.8 billion, down 1% year-over-year. Underlying net profit after tax amounted to US$3.1 billion, a 2% decline that slightly beat analyst expectations. A statutory net loss of US$2.6 billion was reported, driven by US$7.1 billion in pre-tax impairments primarily linked to the CSL Vifor acquisition and underutilized assets.
Separately, CSL Plasma and Haemonetics finalized a supply agreement for NexSys PCS plasma collection devices, providing a modest positive signal to investors. The agreement involves the provision of plasma collection equipment under terms not disclosed.
CSL’s shares have extended gains from the prior session, reflecting investor confidence in the company’s long-term outlook despite near-term earnings pressures.
